Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + verapamil
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Telmisartan + verapamil** is a combination of two antihypertensive agents: telmisartan, an angiotensin II receptor blocker (ARB), and verapamil, a non-dihydropyridine calcium channel blocker. Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, inhibiting the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to a reduction in blood pressure and improvement in metabolic parameters. Verapamil inhibits L-type calcium channels in the heart and vascular smooth muscle, decreasing myocardial contractility and heart rate, and promoting vasodilation. The combination has been investigated for hypertension, and research also supports its use for reducing proteinuria and blood pressure in patients with diabetic nephropathy[2][3][6].
- Other names
- telmisartan + verapamil
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on telmisartan + verapamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + verapamil.